Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)
Pulmonx (LUNG) reported Preferred Stock Liabilities of $207.6 million for Q3 2020, up 1.1% year-over-year from $205.3 million in Q4 2019, and little changed quarter-over-quarter from $207.6 million in Q2 2020.
Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Pulmonx (LUNG) has 2 years of Preferred Stock Liabilities data on file, last reported at $207.6 million in Q3 2020.
- Preferred Stock Liabilities for Q3 2020 came in at $207.6 million, up 1.1% year-over-year; the trailing twelve-month figure through Sep 2020 was $207.6 million (up 1.1% YoY), and the FY2019 annual result was $205.3 million, up 46.11% from the prior year.
- Preferred Stock Liabilities steadied at $207.6 million in Q3 2020 per LUNG's latest filing, from $207.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $207.6 million in Q1 2020 and troughed at $205.3 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Pulmonx | 54.38 Mn | -15.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 207.60 Mn |
| Jun 30, 2020 | 207.60 Mn |
| Mar 31, 2020 | 207.60 Mn |
| Dec 31, 2019 | 205.34 Mn |
| Sep 30, 2019 | 205.34 Mn |